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extracellular matrix formation, which might prevent diabetic
nephropathy.4 More studies are warranted to identify the best
therapeutic strategy for use of sulfonylurea in patients with
diabetic renal disease.
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Regarding Maas’s editorial letter
on serum suPAR levels
To the Editor: On the basis of data from a cohort of 23 adult
patients, the letter from Maas et al.1 concludes that serum
soluble urokinase–type plasminogen activator receptor
(suPAR) levels do not discriminate between primary focal
segmental glomerulosclerosis (FSGS), secondary FSGS, and
minimal change disease (MCD), and cannot be used to predict
the response to a therapeutic course of corticosteroids. They
further note an inverse correlation between the suPAR
concentration and estimated glomerular ﬁltration rate (eGFR).
We advise caution in the interpretation and application of
these ﬁndings for several reasons. First, the patients appear not
to be adequately characterized. For example, there is neither
comment about whether there was biopsy conﬁrmation of all
the cases with FSGS nor clariﬁcation of the criteria used to
distinguish primary from secondary FSGS. The patient with the
highest suPAR is categorized as having steroid-resistant MCD.
However, cross-referencing Figures 1 and 2 indicates that this
patient had the lowest eGFR, presumably o15ml/min. Such
an adverse renal function outcome is very unexpected in
patients with MCD and thus this patient is likely representative
of a FSGS case. Appropriate reclassiﬁcation of some of the
patients by Maas et al.2 may facilitate a more precise
comparison between suPAR and clinical outcomes. Second,
the authors’ conclusions are based on a small sample from a
single institution. In the original paper by Wei et al., data and
conclusions were based on a multicenter biopsy-proven cohort
including 78 pediatric and adult FSGS patients. In addition, we
have presented data from two large well-characterized patients
cohorts—the FSGS PodoNET and Clinical Trial—in which
55–85% of the patients with primary FSGS had an elevated
serum suPAR concentration.3 Although we welcome ongoing
investigation in this novel area, we suggest that information
collected in larger clinical studies involving well-phenotyped
patients should take precedence over data gathered in small
single-center studies where the phenotypic characterization
may be improved. Finally, we point out that MCD and FSGS
are classiﬁcations of diseases that lack speciﬁcity and that may
be amended with a molecular phenotyping approach involving
molecules such as suPAR. Using this strategy, patients with
elevated suPAR levels and poor renal outcomes may indeed
conﬁrm previous publications suggesting suPAR may be a
major cause of FSGS and a biomarker for a poor prognosis in
native and post-transplant recurrent FSGS and nephrotic
syndrome.
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